The company is expected to record revenue of $635.2 million, a sharp drop from the $966 million reported during the same period last year. While Moderna shares have climbed 47% over the past three months, recent trading saw a 2.7% dip as investors weighed the impact of declining Covid-19 vaccine sales on the company's bottom line.

Regulatory Hurdles and Strategy Shifts

The earnings report follows a setback from the Food and Drug Administration, which recently declined to consider Moderna’s application for a new seasonal flu vaccine, citing insufficient testing. This regulatory friction coincides with a broader shift in U.S. health policy under Health Secretary Robert F. Kennedy Jr., a move the company admits is influencing its corporate direction. Chief Executive Stéphane Bancel recently signaled that Moderna would halt investments in new late-stage vaccine trials, citing a climate of vaccine skepticism among U.S. officials.

The Path to 2028

Despite the immediate pressure, investors are focusing on the company’s ability to reach breakeven by 2028. Central to this goal is a combined flu and Covid-19 shot, which UBS analysts view as a more significant growth driver than the standalone flu vaccine. However, the FDA's recent stance suggests this "combo" shot may face its own set of regulatory challenges in the domestic market.

Beyond respiratory vaccines, Moderna is looking toward diversified clinical data to restore investor confidence. The company's roadmap includes several critical milestones:

• A Phase 3 readout for a cancer vaccine developed with Merck is expected in the second half of the year.
• Phase 2 data for a renal cell carcinoma treatment is also on the horizon.
• Additional readouts are anticipated across the company's rare disease and infectious disease portfolios.